FR2983858B1 - NOVEL INHIBITORY COMPOUNDS OF LIPOGENESIS - Google Patents

NOVEL INHIBITORY COMPOUNDS OF LIPOGENESIS

Info

Publication number
FR2983858B1
FR2983858B1 FR1161341A FR1161341A FR2983858B1 FR 2983858 B1 FR2983858 B1 FR 2983858B1 FR 1161341 A FR1161341 A FR 1161341A FR 1161341 A FR1161341 A FR 1161341A FR 2983858 B1 FR2983858 B1 FR 2983858B1
Authority
FR
France
Prior art keywords
lipogenesis
inhibitory compounds
novel inhibitory
hydrogen atom
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1161341A
Other languages
French (fr)
Other versions
FR2983858A1 (en
Inventor
Daniel Redoules
Marion Sylvie Daunes
Stephane Poigny
Marie Florence Galliano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1161341A priority Critical patent/FR2983858B1/en
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Priority to CA2857973A priority patent/CA2857973A1/en
Priority to EP12798298.1A priority patent/EP2788327A1/en
Priority to JP2014545301A priority patent/JP6113744B2/en
Priority to KR1020147018421A priority patent/KR20140101834A/en
Priority to PCT/EP2012/074891 priority patent/WO2013083825A1/en
Priority to AU2012350282A priority patent/AU2012350282A1/en
Priority to BR112014013719A priority patent/BR112014013719A2/en
Priority to CN201280059828.3A priority patent/CN103974937A/en
Priority to US14/363,289 priority patent/US9181189B2/en
Priority to RU2014126394A priority patent/RU2014126394A/en
Priority to MX2014006699A priority patent/MX2014006699A/en
Publication of FR2983858A1 publication Critical patent/FR2983858A1/en
Application granted granted Critical
Publication of FR2983858B1 publication Critical patent/FR2983858B1/en
Priority to HK14110259A priority patent/HK1197057A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention relates to Formula (I), wherein - if X = NH, each of R1, R2, R3, R4 represents a hydrogen atom; if X = N, the core is aromatic, and R2, R3 and R4 represent hydrogen atoms, and R1 = H, halogen, aryl, heteroaryl, alkenyl or acetylenyl; or R1, R2, R3, R4 are defined such that R1 or R2 or R3 or R4 represents a methyl group, and the three other radicals represent a hydrogen atom.
FR1161341A 2011-12-08 2011-12-08 NOVEL INHIBITORY COMPOUNDS OF LIPOGENESIS Expired - Fee Related FR2983858B1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR1161341A FR2983858B1 (en) 2011-12-08 2011-12-08 NOVEL INHIBITORY COMPOUNDS OF LIPOGENESIS
RU2014126394A RU2014126394A (en) 2011-12-08 2012-12-10 NEW COMPOUNDS - LIPOGENESIS INHIBITORS
JP2014545301A JP6113744B2 (en) 2011-12-08 2012-12-10 Novel adipogenesis inhibitor compounds
KR1020147018421A KR20140101834A (en) 2011-12-08 2012-12-10 New lipogenesis inhibitor compounds
PCT/EP2012/074891 WO2013083825A1 (en) 2011-12-08 2012-12-10 New lipogenesis inhibitor compounds
AU2012350282A AU2012350282A1 (en) 2011-12-08 2012-12-10 New lipogenesis inhibitor compounds
CA2857973A CA2857973A1 (en) 2011-12-08 2012-12-10 New lipogenesis inhibitor compounds
CN201280059828.3A CN103974937A (en) 2011-12-08 2012-12-10 Novel adipogenesis inhibitor compounds
US14/363,289 US9181189B2 (en) 2011-12-08 2012-12-10 Lipogenesis inhibitor compounds
EP12798298.1A EP2788327A1 (en) 2011-12-08 2012-12-10 New lipogenesis inhibitor compounds
MX2014006699A MX2014006699A (en) 2011-12-08 2012-12-10 New lipogenesis inhibitor compounds.
BR112014013719A BR112014013719A2 (en) 2011-12-08 2012-12-10 lipogenesis inhibiting compounds
HK14110259A HK1197057A1 (en) 2011-12-08 2014-10-14 New lipogenesis inhibitor compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1161341A FR2983858B1 (en) 2011-12-08 2011-12-08 NOVEL INHIBITORY COMPOUNDS OF LIPOGENESIS

Publications (2)

Publication Number Publication Date
FR2983858A1 FR2983858A1 (en) 2013-06-14
FR2983858B1 true FR2983858B1 (en) 2014-01-03

Family

ID=47324157

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1161341A Expired - Fee Related FR2983858B1 (en) 2011-12-08 2011-12-08 NOVEL INHIBITORY COMPOUNDS OF LIPOGENESIS

Country Status (13)

Country Link
US (1) US9181189B2 (en)
EP (1) EP2788327A1 (en)
JP (1) JP6113744B2 (en)
KR (1) KR20140101834A (en)
CN (1) CN103974937A (en)
AU (1) AU2012350282A1 (en)
BR (1) BR112014013719A2 (en)
CA (1) CA2857973A1 (en)
FR (1) FR2983858B1 (en)
HK (1) HK1197057A1 (en)
MX (1) MX2014006699A (en)
RU (1) RU2014126394A (en)
WO (1) WO2013083825A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130995A1 (en) 2013-06-17 2014-12-18 Chemelectiva S R L DERIVATIVES OF RETINOIC ACID AND PROCESS FOR THEIR PREPARATION
FR3020951B1 (en) * 2014-05-16 2016-06-17 Pierre Fabre Dermo-Cosmetique ASSOCIATION OF TETRAPEPTIDE AND GLYCERYL ESTER FOR THE TREATMENT OF ANDROGENIC ALOPECIA.
FR3026011B1 (en) * 2014-09-24 2019-07-19 Greenpharma COMPOSITION COMPRISING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES, METHOD FOR PRODUCING THE SAME AND USE THEREOF DERMOCOSMAL PHARMACEUTICAL
EP3873415A1 (en) 2018-11-02 2021-09-08 Unilever Global Ip Limited Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849576A (en) * 1964-01-29 1974-11-19 Oreal Process and cosmetic compositions for the treatment of skin and scalp
DE3534421A1 (en) 1985-09-27 1987-04-02 Bayer Ag USE OF THIENYLAMINES AS PERFORMANCE AGENTS, NEW THIENYLAMINE
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5750108A (en) * 1995-09-18 1998-05-12 Regenix Marketing Systems, Inc. Hair treatment system and kit for invigorating hair growth
DE19639818A1 (en) * 1996-09-27 1998-04-02 Hoechst Ag Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
AU2002253441A1 (en) * 2002-04-12 2003-10-27 Silbiotec Due S.A. Medicaments containing glycerophosphoinositol-4-phosphate derivatives
US20040081672A1 (en) * 2002-10-25 2004-04-29 Gupta Shyam K. Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging
US7300957B1 (en) * 2006-06-16 2007-11-27 Whewell Christopher J Skin care compositions
US8143410B2 (en) 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
EP2161290B1 (en) * 2008-09-09 2011-12-14 Agfa Graphics N.V. Radiation curable compositions
FR2940281B1 (en) * 2008-12-22 2011-04-01 Fabre Pierre Dermo Cosmetique ESTER OF DIOL AND POLYUNSATURATED FATTY ACID AS ANTI-ACNE AGENT
FR2954124B1 (en) 2009-12-18 2012-04-06 Fabre Pierre Dermo Cosmetique USE OF 2,3-DIHYDROXYPROPYL DODECANOATE FOR THE TREATMENT OF SEBORRHEA

Also Published As

Publication number Publication date
KR20140101834A (en) 2014-08-20
AU2012350282A1 (en) 2014-06-19
CA2857973A1 (en) 2013-06-13
BR112014013719A8 (en) 2017-06-13
HK1197057A1 (en) 2015-01-02
FR2983858A1 (en) 2013-06-14
US20140315950A1 (en) 2014-10-23
RU2014126394A (en) 2016-01-27
US9181189B2 (en) 2015-11-10
MX2014006699A (en) 2014-07-09
CN103974937A (en) 2014-08-06
WO2013083825A1 (en) 2013-06-13
JP2015502950A (en) 2015-01-29
BR112014013719A2 (en) 2017-06-13
JP6113744B2 (en) 2017-04-12
EP2788327A1 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
CY1120188T1 (en) NAPHYTHRIDINE PRODUCERS USEFUL AS INTEGRINE COMPONENTS avv6
MX358376B (en) New dihydroquinoline-2-one derivatives.
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
MX366095B (en) New bicyclic dihydroquinoline-2-one derivatives.
MX2015001099A (en) New bicyclicpyridine derivatives.
BR112014010813A2 (en) 5-phenyl substituted n- (tetrazol-5-yl) aryl carboxamides and 5-phenyl substituted n- (triazol-5-yl) aryl carboxamides and their use as herbicides
UA112428C2 (en) PESTICIDIC COMPOSITIONS AND ASSOCIATED METHODS
MY169267A (en) New aryl-quinoline derivatives
NZ710052A (en) Novel pyrazol derivatives
CY1117688T1 (en) Tetrahydropyrrolothiazine compounds
MY161134A (en) Piperazine compound having a pgds inhibitory effect
MX2017014661A (en) Process for the preparation of triazines.
BR112012033690A2 (en) calcium salts of compounds as antiinflammatory, immunomodular and antitroliferative agents
BR112014030474A2 (en) new bicyclic thiophenylamide compounds
FR2983858B1 (en) NOVEL INHIBITORY COMPOUNDS OF LIPOGENESIS
EA201001087A1 (en) NEW DIHYDROINDOLONIC COMPOUNDS, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR112016002638A2 (en) new aza-oxo indoles for the treatment and prophylaxis of respiratory syncytial virus infection
CY1117026T1 (en) Heterocyclic compounds for the treatment or prevention of disorders caused by decreased serotonin neurotransmission, NERPIN.
EA201591381A1 (en) NEW BIOACTIVE POLYMERS
BR112013001368A2 (en) 4- (4-haloalkyl-3-thiobenzoyl) pyrazole and use as herbicides thereof
MX366678B (en) New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1- one compounds.
EA201401203A1 (en) 6-PYRIDON-2-CARBAMOILAZOLES AND THEIR APPLICATION AS HERBICIDES
MX2013005753A (en) New biaryl amide derivatives.
BRPI0909789A2 (en) metal carbamate, and processes for preparing metal carbamates and for preparing tolinenediurethane.
BR112015007467A2 (en) imide compound, method of manufacture and use as insecticide

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20180831